Scarica l'app Stockscreener
0.4144
3.29%
-0.0141
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.4285
Aprire:
$0.425
Volume 24 ore:
2.68M
Relative Volume:
0.84
Capitalizzazione di mercato:
$78.44M
Reddito:
$150.71M
Utile/perdita netta:
$-30.94M
Rapporto P/E:
-2.3452
EPS:
-0.1767
Flusso di cassa netto:
$-20.86M
1 W Prestazione:
-5.47%
1M Prestazione:
+1.47%
6M Prestazione:
-70.19%
1 anno Prestazione:
-81.33%
Intervallo 1D:
$0.4007
$0.4399
Intervallo di 1 settimana:
$0.4007
$0.4545
Portata 52W:
$0.382
$2.25
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.4144 | 78.44M | 150.71M | -30.94M | -20.86M | -0.1767 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-03 | Downgrade | Needham | Buy → Hold |
| 2025-06-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision - Yahoo Finance
Heron Therapeutics updates investors on business progress as development pipeline remains the key va - ad-hoc-news.de
HRTXHeron Therapeutics Inc Options - Finviz
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling? - Insider Monkey
Heron Therapeutics Inc (HRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency - The Globe and Mail
Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification - Moomoo
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forbes William P - Moomoo
Heron Therapeutics Inc Actuals & Estimates (NASDAQ:HRTX) - TradingView
Heron Therapeutics Inc Actuals & Estimates (BX:AXD2) - TradingView
Heron Therapeutics, Inc. 8-K Filing: Nasdaq Listing Status, Company Details & Key SEC Disclosures (June 25, 2026) - Minichart
Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price - Stock Titan
Enterprise value to EBITDA forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
Enterprise value to EBIT forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
Price to sales forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
Enterprise value to revenue forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
HRTX Forecast — Price Target — Prediction for 2027 - TradingView
HRTX Q1 2026 Earnings: EPS Misses Estimates Sharply as Losses Widen, Shares Decline 2.33%Pre-Announcement Alert - dars.gov.et
Heron Therapeutics (HRTX) Edges Higher: Testing Key Resistance After Recent GainsCup and Handle - dars.gov.et
Heron Therapeutics Stocklong-term strategy under pressure after reverse split and Nasdaq warning - AD HOC NEWS
Heron Therapeutics (HRTX) Surges 7.8%: Testing Key Resistance at $0.44Advance Decline Volume - dars.gov.et
Heron Therapeutics Inc (HRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Heron Therapeutics Inc (HRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HRTX Stock Price, Quote & Chart - ChartMill
Heron Therapeutics (NASDAQ: HRTX) CFO exercises RSUs and withholds shares for taxes - Stock Titan
Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting - Investing.com India
Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Heron Therapeutics Inc (HRTX) Institutional Confidence - TradingKey
Heron Therapeutics Inc (HRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Heron Therapeutics Inc (HRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting By Investing.com - Investing.com South Africa
Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan - Stock Titan
HRTX: All director nominees and proposals were approved, with no questions from stockholders - TradingView
HRTX Q1 2026 Earnings: Deep EPS Miss Triggers 10.7% Stock DeclineGuidance Accuracy Score - newsline.com
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade) - Seeking Alpha
Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares - Stock Titan
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $2 - Moomoo
TANG KEVIN C's Strategic Acquisition in Aurinia Pharmaceuticals Inc - GuruFocus
HRTX Maintains Buy Rating -- Price Target Lowered to $2.00 by HC Wainwright - GuruFocus
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents - The Globe and Mail
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
HRTX Downgraded by Needham -- Outlook Adjusted to Hold - GuruFocus
Heron Therapeutics to Appeal Delaware Court Ruling Invalidating CINVANTI® Patents - Minichart
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
CINVANTI patent claims invalidated as Heron Therapeutics (NASDAQ: HRTX) plans appeal - Stock Titan
Heron announces U.S. district court decision regarding Cinvanti patents - TipRanks
Heron Therapeutics loses patent case over Cinvanti drug - Investing.com UK
Heron Therapeutics loses patent case over Cinvanti drug By Investing.com - Investing.com India
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Heron Therapeutics Inc Azioni (HRTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):